دورية أكاديمية

Allogenic Adipose Tissue-Derived Stromal/Stem Cells and Vitamin D Supplementation in Patients With Recent-Onset Type 1 Diabetes Mellitus: A 3-Month Follow-Up Pilot Study

التفاصيل البيبلوغرافية
العنوان: Allogenic Adipose Tissue-Derived Stromal/Stem Cells and Vitamin D Supplementation in Patients With Recent-Onset Type 1 Diabetes Mellitus: A 3-Month Follow-Up Pilot Study
المؤلفون: Debora B. Araujo, Joana R. Dantas, Karina R. Silva, Débora L. Souto, Maria de Fátima C. Pereira, Jessica P. Moreira, Ronir R. Luiz, Cesar S. Claudio-Da-Silva, Monica A. L. Gabbay, Sergio A. Dib, Carlos E. B. Couri, Angelo Maiolino, Carmen L. K. Rebelatto, Debora R. Daga, Alexandra C. Senegaglia, Paulo R. S. Brofman, Leandra Santos Baptista, José E. P. Oliveira, Lenita Zajdenverg, Melanie Rodacki
المصدر: Frontiers in Immunology, Vol 11 (2020)
بيانات النشر: Frontiers Media S.A., 2020.
سنة النشر: 2020
المجموعة: LCC:Immunologic diseases. Allergy
مصطلحات موضوعية: type 1 diabetes, pancreatic function, transplant, adipose tissue-derived stromal/stem cells, vitamin D, Immunologic diseases. Allergy, RC581-607
الوصف: Objective: To evaluate the short term safety and potential therapeutic effect of allogenic adipose tissue-derived stromal/stem cells (ASCs) + cholecalciferol in patients with recent-onset T1D.Methods: Prospective, phase II, open trial, pilot study in which patients with recent onset T1D received ASCs (1 × 106 cells/kg) and cholecalciferol 2000 UI/day for 3 months (group 1) and were compared to controls with standard insulin therapy (group 2). Adverse events, C-peptide (CP), insulin dose, HbA1c, time in range (TIR), glucose variability (continuous glucose monitoring) and frequency of CD4+FoxP3+ T-cells (flow cytometry) were evaluated at baseline (T0) and after 3 months (T3).Results: 13 patients were included (8: group 1; 5: group 2). Their mean age and disease duration were 26.7 ± 6.1 years and 2.9 ± 1.05 months. Adverse events were transient headache (n = 8), mild local reactions (n = 7), tachycardia (n = 4), abdominal cramps (n = 1), thrombophlebitis (n = 4), mild floaters (n = 2), central retinal vein occlusion (n = 1, complete resolution). At T3, group 1 had lower insulin requirement (0.22 ± 0.17 vs. 0.61±0.26IU/Kg; p = 0.01) and HbA1c (6.47 ± 0.86 vs. 7.48 ± 0.52%; p = 0.03) than group 2. In group 1, 2 patients became insulin free (for 4 and 8 weeks) and all were in honeymoon at T3 (vs. none in group 2; p = 0.01). CP variations did not differ between groups (−4.6 ± 29.1% vs. +2.3 ± 59.65%; p = 0.83).Conclusions: Allogenic ASCs + cholecalciferol without immunosuppression was associated with stability of CP and unanticipated mild transient adverse events in patients with recent onset T1D.ClinicalTrials.gov registration: NCT03920397.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1664-3224
العلاقة: https://www.frontiersin.org/article/10.3389/fimmu.2020.00993/fullTest; https://doaj.org/toc/1664-3224Test
DOI: 10.3389/fimmu.2020.00993
الوصول الحر: https://doaj.org/article/d415c715ff804350b123ce8576df0eb6Test
رقم الانضمام: edsdoj.415c715ff804350b123ce8576df0eb6
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:16643224
DOI:10.3389/fimmu.2020.00993